CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable

[July 23, 2014]

NanoViricides President Dr. Diwan was an Invited Participant at the Prestigious CEO Roundtable

WEST HAVEN, Conn. --(Business Wire)--

NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") reports that its President, Dr. Anil Diwan, was invited to participate in the 29th Annual Chief Executive of the Year Gala Reception & Dinner held at the New York Stock Exchange on Thursday, July 17, 2014. In addition, he was also invited to participate in the CEO Roundtable Discussion, on the topic of "Enhancing CEO Effectiveness by Redefining the Role of the CFO", which was held prior to the Reception, from 4pm to 5:50pm.

The "CEO Roundtable Discussion" was moderated by Mr. J.P. Donlon, Editor-in-Chief, Chief Executive Magazine, with Ms. Arleen Thomas, Senior Vice President, AICPA, serving as an Expert Advisor. Participants included Fortune 500 Chief Executives, led by Mr. David Cote, CEO of Honeywell (News - Alert), Inc., and peers drawn from successful businesses representing industry segments from Manufacturing, Services, Technology, Operations, to Biopharma and Healthcare.

Dr. Diwan discussed the special skills that the CFO of a typical pre-revenue Biotech/Biopharma Company needs to possess. He commented that the CFO of such a company needs to develop particular expertise in strategies and tactics to be employed in an R&D-intensive setting, keeping in mind that not all of the R&D pays off, and that not all of the R&D has a specific project allocability. In this situation, the role of the CFO needs to be to help the CEO and the President with the assessment of the impact of various R&D strategies and financing requirements, taken together, on generating long term success for the Company, and thereby generating long term value for the investors.

Mr. Bob Iger, Chairman and CEO of the Walt Disney (News - Alert) Company, was named the "2014 CEO of the Year" by the Chief Executive Magazine, and felicitated at an invitation-only Gala Reception and Dinner event hosted by NYSE Euronext and the Chief Executive Group at the New York Stock Exchange on July 17, 2014. CEO of the Year is an honor bestowed upon an outstanding corporate leader, nominated and selected by a group of CEO peers (http://www.marketwatch.com/story/bob-iger-chairman-and-ceo-the-walt-disney-company-is-named-2014-ceo-of-the-year-by-chief-executive-magazine-2014-07-14).

About Chief Executive Group

Chief Executive Group�produces Chief Executive magazine (published since 1977), and chiefexecutive.net, including e-newsletters and online content, as well as conferences and roundtables that enable top corporate officers to discuss key subjects and share their experiences within a community of peers. The Group also facilitates the annual "CEO of the Year," a prestigious honor bestowed upon an outstanding corporate leader, nominated and selected by a group of peers. Visit www.chiefexecutive.net for more information.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter